The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer
Abstract
We are evaluating the use of electroporation (EP) to deliver a novel DNA vaccine, p.DOM-PSMA(27). This vaccine encodes a domain (DOM) of fragment C of tetanus toxin to induce CD4(+) T cell help, fused to a tumor-derived epitope from prostate-specific membrane antigen (PSMA) for use in HLA-A2(+) patients with recurrent prostate cancer. We report on safety and tolerability and on antibody response to DOM as a first indication of the effect of EP in patients. In this open label phase I/II, two-arm, dose escalation trial DNA was delivered either by intramuscular injection or by intramuscular injection followed by EP (DNA+EP), with five patients per dose level. Three vaccinations were given at 0, 4, and 8 weeks,with booster doses at 24 and 48 weeks; here we allowed crossover between study arms if supported by the safety and immunological data. In the 20 patients in the first two dose cohorts we observed that beyond brief and acceptable pain at the injection site, EP did not appear to add toxicity to the vaccination. We evaluated humoral responses to DOM. Low anti-DOM IgG antibody responses were observed after intramuscular injection of DNA without EP (at week 12: mean 1.7- vs. 24.5-fold increase over baseline with DNA+EP). These could be boosted by delivery of DNA+EP at later time points. Delivery of DNA+EP at all five vaccinations yielded the highest levels of anti-DOM antibody. Responses persisted to 18 months of follow-up. These data establish EP as a potent method for stimulating humoral responses induced by DNA vaccination in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distribution of DNA Vaccines Determines Their Immunogenicity After Intramuscular Injection in Mice
Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M. J., Chen, M., Otten, G. R., Ulmer, J. B., Donnelly, J. J., Ott, G., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2850 · Cited by 327
Cited by
Electroporation delivery of DNA vaccines: prospects for success
Sardesai, N. Y., & Weiner, D. B. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.008 · Cited by 416
Technologies for enhanced efficacy of DNA vaccines
Saade, F., & Petrovsky, N. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.188 · Cited by 309
Immunotherapy Against HPV16/18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses
Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004414 · Cited by 282
DNA vaccine for cancer immunotherapy
Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C.-F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.980686 · Cited by 276
Touchard, E., Berdugo, M., Bigey, P., El Sanharawi, M., Savoldelli, M., Naud, M.-C., Jeanny, J.-C., & Behar-Cohen, F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.304 · Cited by 63
Metadata
- Authors
- Low, L., Mander, A., McCann, K., Dearnaley, D., Tjelle, T., Mathiesen, I., Stevenson, F., & Ottensmeier, C. H.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2009-11
- Volume
- 20
- Issue
- 11
- Pages
- 1269-1278
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1979162850
- Cited by
- 179
- References
- 1
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. https://app.cochat.ai/papers/10.1089/hum.2009.067
- The paper
- Low, L., Mander, A., McCann, K., Dearnaley, D., Tjelle, T., Mathiesen, I., Stevenson, F., & Ottensmeier, C. H. (2009). DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Human Gene Therapy. https://doi.org/10.1089/hum.2009.067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.